AbbVie Inc.
Historical Data
View all| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 3, 2026 | $5.46 | $5.88 | $5.29 | $5.74 | 19.78M |
| Jul 2, 2026 | $5.25 | $5.67 | $4.95 | $5.46 | 22.02M |
| Jul 1, 2026 | $5.40 | $5.48 | $5.12 | $5.25 | 10.73M |
| Jun 30, 2026 | $5.23 | $5.55 | $5.12 | $5.40 | 26.27M |
| Jun 29, 2026 | $5.20 | $5.27 | $5.14 | $5.23 | 10.99M |
| Jun 28, 2026 | $5.10 | $5.32 | $4.95 | $5.20 | 22.25M |
| Jun 27, 2026 | $5.19 | $5.30 | $4.99 | $5.10 | 25.38M |
| Jun 26, 2026 | $5.38 | $5.47 | $4.90 | $5.19 | 20.07M |
Company Overview
AbbVie Inc. operates in the consumer discretionary space within the Consumer Discretionary sector. The company generates the majority of its revenue from operating momentum, and has built a durable competitive position through scale, brand, and continued reinvestment. It serves customers globally and is headquartered in the United States. Reported figures on this page are generated for demonstration and are not investment advice.
Leadership
Board 10 · Independent 7 of 10| Date | Firm | Target | Rating |
|---|---|---|---|
| Jul 2 | Needham | $6.72 | Strong Buy |
| Jul 1 | Rosenblatt | — | Overweight |
| Jun 19 | Morgan Stanley | $10.20 | Buy |
| Jun 18 | Barclays | $8.08 | Overweight |
| Jun 7 | Truist Financial | — | Overweight |
| May 25 | BofA Securities | $7.80 | Strong Buy |
Politician Trades
View allWhat's Happening Right Now
- Sep 3, 2026 · M&A ↗ — AbbVie completed an $11B acquisition of Apogee Therapeutics.
- Sep 3, 2026 · Pipeline ↗ — AbbVie succeeded in a late-stage trial for a multiple myeloma drug.
- Sep 18, 2026 · Product ↗ — New VRAYLAR data strengthened the company's case for treating mood disorders.
- Sep 18, 2026 · Clinical ↗ — AbbVie's depression drug showed improved mood and daily life outcomes in real-world studies.
- Sep 17, 2026 · R&D ↗ — AbbVie studied skin effects in patients on weight-loss drugs, noting perceived facial de-aging.
Snapshot
AbbVie generated $61.16B in FY2025 revenue, up 8.6% year-over-year, while net income came in at $4.23B for a 6.9% margin. Despite positive net income, the company reported an operating loss of $241.00M, alongside substantial R&D spending of $9.10B (15% of revenue). Free cash flow remained robust at $17.82B, but the balance sheet carries $61.44B in total debt against just $5.23B in cash and equivalents. This combination of strong top-line growth and cash generation contrasts with thin operating profitability and a heavily leveraged capital structure.
Bottom Line
AbbVie pairs solid revenue growth (+8.6% YoY) and strong free cash flow ($17.82B) with recent pipeline wins and an $11B Apogee acquisition, signaling continued investment in future growth drivers like neuroscience and oncology. However, the reported operating loss, thin 6.9% net margin, and elevated $61.44B debt load versus only $5.23B cash highlight balance-sheet and profitability pressures investors should weigh against the growth narrative. The tradeoff is between near-term margin/leverage concerns and longer-term pipeline optionality from recent trial successes and M&A.